PBM Express Scripts Fights Back

After Gilead Sciences’ head of worldwide commercial operations blamed PBMs for keeping drug prices high in an article appearing on Bloomberg News, Express Scripts, one of the largest PBMs, fought back in a letter requesting Gilead lower the price of each of its drugs in the hepatitis C franchise to $50,000 per course of treatment instead of the current price of $89,000. Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.